Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel and Cisplatin in Neo-adjuvant Treatment of Bladder Cancer
NCT01616875Phase 2Completed
- Sponsor
- University Hospitals Bristol and Weston NHS Foundation Trust
- Start
- Jul 2012
- Primary completion
- Nov 2017
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabazitaxel ginsenoside liposome injection in transitional cell carcinoma of the urinary bladder (TCC), sponsored by University Hospitals Bristol and Weston NHS Foundation Trust. Primary endpoint: Overall Pathological Response Rate at 15 weeks. Started Jul 2012; status: completed.
02
Drugs
cabazitaxel ginsenoside liposome injection
03
Conditions
transitional cell carcinoma of the urinary bladder (TCC)
Beyond the preview
Go deeper on NCT01616875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01616875.